Hemostemix Announces Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference on Wednesday, October 26th at 12:00 EDT. Attendees may use the following link to attend: (https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=hmtxf). ABOUT HEMOSTEMIX...
2022-10-25 11:36 AM EDT
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
Calgary, Alberta--(Newsfile Corp. - October 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.'s study of NCP-01. The spinal cord injury repair study will focus on the improvement of motor function and the decrease of pain following the injection of NCP-01 into the spinal fluid pathway of small animals. The global neuropathic pain market was...
2022-10-19 9:43 AM EDT
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on...
2022-10-04 9:00 AM EDT
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board. Dr. von Schwarz is a US based world renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine at UCLA and UC Riverside. He joined Cedars Sinai Medical Center and UCLA as Director of...
2022-09-27 9:00 AM EDT
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board. Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and Health Sciences at McGill University, the Director of the McGill Regenerative Medicine Network, and a Professor in the Department of Pharmacology and...
2022-09-20 8:45 AM EDT
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board. Dr. Giannetti received her Medical Degree from McGill University. After training in cardiology at McGill, she went on to pursue a Fellowship in Heart Failure and Cardiac Transplantation at Stanford University in California. She returned to McGill to...
2022-09-16 10:32 AM EDT
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board. Since 2019, Dr. Johannes Grillari is the director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma) - the Research Center in cooperation with AUVA, Vienna, Austria which is the central research unit of seven trauma centers and four rehabilitation...
2022-09-15 11:14 AM EDT
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board. Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Transplantation Program, and Director of the Mechanical Circulatory Support Program. He is also Associate Member of the McGill University Department...
2022-09-14 1:02 PM EDT
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") invites individuals, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at 12:00 ET today https://goto.webcasts.com/starthere.jsp?ei=1552113&tp_key=93e040bf55&sti=hmtfx. ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy company, founded...
2022-09-14 10:26 AM EDT
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc. Mr. Abraham has more than 25 years of financing, business development, and governance and risk management experience in a broad range of roles encompassing private equity investment transactions, including sales and distribution of alternative investments, in Toronto, New...
2022-09-13 9:00 AM EDT
Hemostemix Announces A Clarification
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") received numerous enquiries about the press release of August 30, 2022. This press release details the results in a table format and clarifies a misprint. Table 1 is a summary of the patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell precursors (ACP-01) as a treatment for heart failure (ischemic and non-ischemic...
2022-08-31 1:27 PM EDT
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the results of its Phase II Clinical Trial and the results of a new retrospective study of patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell precursors (ACP-01) as a treatment for heart failure (ischemic and non-ischemic dilated cardiomyopathy). The 2021 American Heart Association estimated the...
2022-08-30 9:00 AM EDT
Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - August 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a tranche of its previously announced non-brokered private placement of units ("Units") as announced on August 19, 2022 for gross proceeds of $192,000 (the "Offering"). The Offering consisted of the issuance of an aggregate of 640,000 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of the Company...
2022-08-22 4:50 PM EDT
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - August 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to five Million Units priced at $0.30 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55...
2022-08-19 11:34 AM EDT
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - August 12, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a second tranche of its previously announced non-brokered private placement of units ("Units") as announced on May 19, 2022 for gross proceeds of $1,364,710.10 (the "Offering"). The Offering consisted of the issuance of an aggregate of 4,549,034 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of...
2022-08-12 8:55 AM EDT
Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - June 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it closed the first tranche of its non-brokered private placement of units ("Units") announced on May 19, 2022, for gross proceeds of $690,388.80 (the "Offering"). The Offering consisted of the issuance of an aggregate of 2,301,296 Units at a price of $0.30 per Unit. Each Unit consists of one common share in the capital of the Company ("Common...
2022-06-22 4:02 PM EDT
Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
Calgary, Alberta--(Newsfile Corp. - June 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has incorporated PreCerv Inc. ("PreCerv"), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to the following: Neuropathic pain syndromes. Traumatic...
2022-06-14 8:21 AM EDT
Hemostemix Announces Financing
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to 15 Million Units priced in the context of the market. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.55 per Common Share for a...
2022-05-19 4:55 PM EDT
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Peter Pavlin, P.Eng. to the position of Vice President Operations. Mr. Pavlin earned his Bachelor of Applied Science and Master of Engineering degrees in Mechanical Engineering from the University of Toronto, Canada's top ranked engineering school. He has held progressive positions managing and directing...
2022-05-19 11:29 AM EDT
Hemostemix Announces Rick Groome as Special Advisor to The CEO
Calgary, Alberta--(Newsfile Corp. - May 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce Mr. Richard ("Rick") Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau Lemire and Groome Capital, which funded many successful biotechnology companies. "I...
2022-05-16 9:49 AM EDT